Molecular Partners (NASDAQ:MOLN) Posts Earnings Results, Beats Estimates By $0.02 EPS

Molecular Partners (NASDAQ:MOLN) announced its quarterly earnings results on Tuesday. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.02, FiscalAI reports.

Molecular Partners Stock Performance

Shares of NASDAQ MOLN opened at $4.40 on Tuesday. The stock’s 50-day moving average is $4.03 and its 200 day moving average is $4.23. The stock has a market cap of $177.65 million, a price-to-earnings ratio of -2.27 and a beta of 1.08. Molecular Partners has a 1-year low of $3.53 and a 1-year high of $5.36.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Molecular Partners in a report on Wednesday, July 8th. HC Wainwright reissued a “buy” rating on shares of Molecular Partners in a report on Monday, July 6th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $8.38.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Molecular Partners stock. SmartHarvest Portfolios LLC acquired a new stake in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 12,311 shares of the company’s stock, valued at approximately $54,000. Institutional investors own 26.55% of the company’s stock.

Molecular Partners Company Profile

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.